CLINICAL_TRIALS
trial_result
· 2018-09-10
Clinical Trial Update: BAX 326 (rFIX) Continuation Study [Phase 3]
Summary
Phase 3 continuation study of BAX 326 (recombinant factor IX) for Hemophilia B completed; results posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Baxalta now part of Shire | Conditions: Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2018-09-10